National and Kapodistrian University of Athens
Συνδυασμός συνεχούς μηριαίου αποκλεισμού με ροπιβακαΐνη και ενδοφλέβιας χορήγησης παρεκοξίμπης σε ολικές αρθροπλαστικές γόνατος για μετεγχειρητική αναλγησία: κλινική αξιολόγηση
Abstract
dc:descriptionIntroduction: Up until now, the optimal strategy for postoperative pain management after total knee arthroplasty (TKA) remains to be elucidated. Continuous regional tecniques have gained a well established role. The intravenous administration of parecoxib could provide significant pain relief in surgical operations that require additional forms of analgesia. However, very little is known about its effects on the anxiety levels of patients before a surgical procedure. The current investigation aimed to examine the analgesic efficacy and the opioid sparing effects of intravenous parecoxib in combination with continuous femoral blockade. Also another aim of this prospective study was to investigate whether parecoxib, pre-emptively administered, has an effect on anxiety levels experienced post-surgically after total knee arthroplasty (TKA) and if it influences the reported pain of the procedure itself. Study design: Randomized, double-blind, prospective trial.Methods: A total of 90 patients were included in the study after obtaining written consent. They all underwent TKA under subarachnoid anesthesia and received continuous femoral block initially as a bolus with 20 mL of ropivacaine 0.75%. Infusion of 0.2% on 10 mL/h followed. Patients were randomized into 2 groups. Group D (N=45) and Group P ( N= 45) received parecoxib and placebo drug (N/S 0,9%) intravenously instead of parecoxib, respectively at 12 hour time intervals. Visual analog scale (VAS) pain scores were obtained at different time intervals including 4, 8, 12, 24 and 36 hours. The pain scores were measured with patients in a resting position. Morphine was also be administered with a patient controlled analgesia (PCA) pump if the specified analgesia was deemed inadequate (VAS > 5). Haemodynamic parameters were recorded in the above specific time intervals intra and postoperatively. Bromage scores were collected as well as morphine consumption on the above time intervals. Transfusion requirements and haemoglobin levels were also recorded as well as rehabilitation aspects like range of motion. All patients were asked to fill in the questionnaires STAI1 and STAI2 in order to evaluate anxiety levels pre- and post-surgically, respectively. One of the main aims was to distinguish personality-trait anxiety from state anxiety, i.e. anxiety experience due to the actual perioperative events and the actual pain endured. Results:Parecoxib provided greater relief than placebo following TKA. The VAS pain scores measured at rest were statistically significantly lower in parecoxib-treated patients compared to the placebo group (P = 0.007) at 4 (P = 0.044), 12 (P = 0.001), and 24 hours (P = 0.012), postoperatively. Patients receiving parecoxib consumed less morphine at all time intervals than patients receiving placebo, with borderline statistical significance (P = 0.054). In each time period, all patients receiving continuous femoral block irrespectively of the treatment group, required low morphine doses.The group receiving parecoxib had statistically significant lower anxiety levels both for personality trait anxiety and state anxiety. There was no significant statistical difference between the two groups as far as the haemodynamic parameters and the transfusion requirements and the haemoglobin levels . The parecoxib group demonstrated better values on the ROM scale and faster rehabilitation.Conclusions: Intravenous parecoxib in combination with continuous femoral block provided superior analgesic efficacy and opioid sparing effects in patients undergoing TKA. In addition to this, based on our findings, parecoxib had significant anxiolytic effect.Trial Registration: Current Controlled Trials: NCT02185924
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sarridou, Despoina
- Σαρρίδου, Δέσποινα
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39675